|
CDP-Choli 250 MG - 60 CP.
|
$69.90
|
 |
"CDP Choline 250 mg 60 capsules - Montiff
Ingredients per 1 capsule:
Cytidine 5-diphospocholine 250 mg
Other ingredients: Microcrystalline cellulose, magnesium stearate, gelatin.
Suggested use: As a dietary supplement, take one to two capsules per day as needed, or as recommended by a health care professional. To be used as a dietary supplement in a normal food program. It is recommended that this product be taken with vitamins and minerals.
Contains NO starch, corn, milk, wheat, yeast, sugar, eggs, salt, artificial colors, binders, flavors, preservatives or fish derivatives.
CDP-Choline Recommendations
CDP-choline has been used successfully in Europe for many years but clinical experience in the US is limited. This nutrient appears to have a more direct and immediate effect on the brain than its cousin choline. However, it is difficult to predict at this time the long-term benefits or risks of regular use. CDP-choline is a promising nutrient and I suspect that with time it will become more popular.
CDP-Choline Research Update
CDP-choline in the treatment of chronic cerebrovasculopathies.
Arch Gerontol Geriatr. 1994 May-Jun;18(3):161-8.
Ninety-two patients affected by chronic cerebrovasculopathy were treated with cytidine diphosphate choline ( CDP-choline ) 1000 mg/day i.m. or with placebo, in a double-blind study. Two cycles of therapy of 4 weeks each were performed, with an interval of 1 week. There were 46 patients in each group with chronic cerebrovascular diseases, and the two groups were comparable as far as mental deterioration was concerned. The comparison between the two groups revealed significant improvements in the CDP-choline group compared with the placebo group in some of the attention capabilities (decrease in the number of wrong answers at the Toulouse-Piéron test), of the mnemonic capabilities ('General Information' subtest of Randt Memory test) and behavioral capabilities (SCAG 'affective disturbances' score). No side-effects were detected in the CDP-choline group.
CDP-choline increases plasma ACTH and potentiates the stimulated release of HGH, TSH and LH: the cholinergic involvement.
Fundam Clin Pharmacol. 2004 Oct;18(5):513-523. Abstract In the present study, we investigated the effect of intracerebroventricular (i.c.v.) administration of cytidine-5'-diphosphate (CDP) choline on plasma adrenocorticotropin (ACTH), serum growth hormone (GH), thyroid stimulating hormone (TSH), follicle stimulating hormone (FSH) and luteinizing hormone (LH) levels in conscious rats. The involvement of cholinergic mechanisms in these effects was also determined. In basal conditions, CDP-choline increased plasma ACTH levels dose- and time-dependently, but it did not affect the TSH, GH, FSH and LH levels. In stimulated conditions, i.c.v. administration of CDP-choline produced an increase in clonidine-stimulated GH, thyrotyropin-releasing hormone (TRH)-stimulated TSH, LH-releasing hormone (LHRH)-stimulated LH, but not FSH levels. Injection of equimolar dose of choline (1 μmol, i.c.v.) produced similar effects on hormone levels, but cytidine (1 μmol, i.c.v.) failed to alter plasma levels of these hormones. Pretreatment with hemicholinium-3, a neuronal high affinity choline uptake inhibitor, (20 μg, i.c.v.) completely blocked the observed hormone responses to CDP-choline. The increase in plasma ACTH levels induced by CDP-choline was abolished by pretreatment with mecamylamine, a nicotinic receptor antagonist, (but not atropine, a muscarinic receptor antagonist. The increase in stimulated levels of serum TSH by CDP-choline was blocked by atropine but not by mecamylamine pretreatment. However, CDP-choline induced increases in serum GH and LH levels were greatly attenuated by both atropine and mecamylamine pretreatments. The results show that CDP-choline can increase plasma ACTH and produce additional increases in serum levels of TSH, GH and LH stimulated by TRH, clonidine and LHRH, respectively. The activation of central cholinergic system, mainly through the presynaptic mechanisms, was involved in these effects. Central nicotinic receptors solely mediated the increase in plasma ACTH levels while the activation of central muscarinic receptors was involved in the increase in TSH levels. Both muscarinic and nicotinic receptor activations, separately, mediated the increases in serum GH and LH levels after CDP-choline.
Chronic treatment with a precursor of cellular phosphatidylcholine ameliorates morphological and behavioral effects of aging in the mouse [correction of rat] hippocampus.
Ann N Y Acad Sci. 2004 Jun;1019:41-3.
Normal aging is commonly associated with a decline in memory, mainly for that related with newly acquired information. The hippocampal formation (HF) is a brain region that has been implicated in this dysfunction. Within the HF there are several cellular types, such as pyramidal cells, granule neurons of the dentate gyrus, and astrocytes. CDP-choline is a well-known intermediate in the biosynthesis of phosphatidylcholine, a phospholipid essential for neuronal membrane preservation and function; thus, this compound would attenuate the process of neuronal aging. To test this, three groups of male mice were used in this study. An adult 12-month-old group, a 24-month-old, and an old experimental group (OEG) were administered orally a solution of CDP-choline (150 mg/kg per day) from 12 up to 24 months. Experimental observations suggest that CDP-choline has a positive effect on memory (reference errors were attenuated), and hippocampal morphology resembled that of younger animals. " |
Home
View
My SMHP Cart
Contact
SMHP
Women's
Health
